LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

Written by Emily J. Thompson, Senior Investment Analyst

LSB%

Source: PRnewswire

Updated: Sep 22 2025

0mins

Source: PRnewswire

Trading Suspension: LakeShore Biopharma's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market due to non-compliance with minimum bid price requirements, effective September 22, 2025.
OTC Market Transition: The company's shares and warrants will begin trading on the OTC Pink Open Market under new symbols, while maintaining its business operations and commitment to transparency with shareholders.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Lumen Technologies Stock Surges 46.3% in 2025 Driven by New Partnerships

XRP Predicted to Surpass $4 in 2026 Amid Low Market Sentiment

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch